8-K filed January 22, 2025, 6:59 PM ET ticker ALXO CIK 0001810182

leadership confidence high sentiment positive materiality 0.65

ALX Oncology appoints Harish Shantharam as CFO and adds Klencke, Takimoto to board

ALX ONCOLOGY HOLDINGS INC

Harish Shantharam named CFO effective Jan 21, 2025; base salary $490k, target bonus 40%, option for 600k shares.
Barbara Klencke, M.D. and Chris Takimoto, M.D., Ph.D. appointed to Board effective Jan 18, 2025; each receives initial option for 40,400 shares.
Shantharam previously CFO of CymaBay ($4.3B Gilead acquisition); held finance roles at Gilead and Amgen.
Klencke serves on boards of Xencor, TScan, Immune-Onc; Takimoto is CMO at START Center, former CMO at Forty Seven ($4.9B Gilead acquisition).
Board expanded to 6 members; new committee assignments: Klencke on Audit/R&D, Takimoto on Compensation/R&D.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Barbara Klencke

Director

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2025-01-18
Filed: January 22, 2025, 6:59 PM ET

Effective January 18, 2025, the Board appointed Barbara Klencke, M.D. to serve as a Class II director of the Board

Role change

Shelly Pinto

Interim Chief Financial Officer

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2025-01-21
Successor: Harish Shantharam
Filed: January 22, 2025, 6:59 PM ET

Ms. Pinto resigned as the interim Chief Financial Officer effective as of the same date and will remain the Company’s Senior Vice President, Finance and Chief Accounting Officer and the principal accounting officer.

Appointed

Chris Takimoto

Director

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2025-01-18
Filed: January 22, 2025, 6:59 PM ET

and Chris Takimoto, M.D., Ph.D., F.A.C.P., to serve as a Class III director of the Board

Appointed

Harish Shantharam

Chief Financial Officer

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2025-01-21
Filed: January 22, 2025, 6:59 PM ET

Effective January 21, 2025, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Harish Shantharam to the office of Chief Financial Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Barbara Klencke was appointed as Director at ALX ONCOLOGY HOLDINGS INC.

Action: appointed
Role: Director

Exact text from the filing

Effective January 18, 2025, the Board appointed Barbara Klencke, M.D. to serve as a Class II director of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Shelly Pinto resigned as Interim Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.

Action: resigned
Role: Interim Chief Financial Officer

Exact text from the filing

Ms. Pinto resigned as the interim Chief Financial Officer effective as of the same date and will remain the Company’s Senior Vice President, Finance and Chief Accounting Officer and the principal accounting officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Chris Takimoto was appointed as Director at ALX ONCOLOGY HOLDINGS INC.

Action: appointed
Role: Director

Exact text from the filing

and Chris Takimoto, M.D., Ph.D., F.A.C.P., to serve as a Class III director of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Harish Shantharam was appointed as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective January 21, 2025, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Harish Shantharam to the office of Chief Financial Officer

View on SEC.gov

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-25-007532

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.